Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

作者：Kieffer Tara L^*; De Meyer Sandra; Bartels Doug J; Sullivan James C; Zhang Eileen Z; Tigges Ann; Dierynck Inge; Spanks Joan; Dorrian Jennifer; Jiang Min; Adiwijaya Bambang; Ghys Anne; Beumont Maria; Kauffman Robert S; Adda Nathalie; Jacobson Ira M; Sherman Kenneth E; Zeuzem Stefan; Kwong Ann D; Picchio Gaston

来源：PLos One, 2012, 7(4): e34372.

DOI：10.1371/journal.pone.0034372

Background: In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic changes could be observed in TVR-treated patients who did not achieve an SVR. %26lt;br%26gt;Methods: Population sequence analysis of the NS3N4A region was performed in patients who did not achieve SVR with TVR-based treatment. %26lt;br%26gt;Results: Resistant variants were observed after treatment with a telaprevir-based regimen in 12% of treatment-naive patients (ADVANCE; T12PR arm), 6% of prior relapsers, 24% of prior partial responders, and 51% of prior null responder patients (REALIZE, T12PR48 arms). NS3 protease variants V36M, R155K, and V36M+R155K emerged frequently in patients with genotype 1a and V36A, T54A, and A156S/T in patients with genotype 1b. Lower-level resistance to telaprevir was conferred by V36A/M, T54A/S, R155K/T, and A156S variants; and higher-level resistance to telaprevir was conferred by A156T and V36M+R155K variants. Virologic failure during telaprevir treatment was more common in patients with genotype 1a and in prior PR nonresponder patients and was associated with higher-level telaprevir-resistant variants. Relapse was usually associated with wild-type or lower-level resistant variants. After treatment, viral populations were wild-type with a median time of 10 months for genotype 1a and 3 weeks for genotype 1b patients. %26lt;br%26gt;Conclusions: A consistent, subtype-dependent resistance profile was observed in patients who did not achieve an SVR with telaprevir-based treatment. The primary role of TVR is to inhibit wild-type virus and variants with lower-levels of resistance to telaprevir. The complementary role of PR is to clear any remaining telaprevir-resistant variants, especially higher-level telaprevir-resistant variants. Resistant variants are detectable in most patients who fail to achieve SVR, but their levels decline over time after treatment.

• 出版日期2012-4-12